Krcméry V, Fuchsberger P, Trupl J, Sufliarsky J, Spanik S, Koza I, Kusenda Z, Korec S, Svec J, Durkovic P
Department of Clinical Oncology, Postgraduate Medical School, Bratislava, CSFR.
Chemotherapy. 1992;38(4):271-4. doi: 10.1159/000239011.
58 granulocytopenic patients with confirmed bronchopneumonia were divided retrospectively into two groups for this pilot study: group 1 included neutropenic patients with venous catheters who were treated with ciprofloxacin (CIP; 200-300 mg, i.v. b.i.d.) + vancomycin (VAN; 0.5-1 g, i.v. b.i.d.), and group 2, which included patients without venous catheters treated with ceftazidime (2 g, i.v. t.i.d.) + gentamicin (1 mg/kg, i.v. t.i.d.). Pneumonia was diagnosed clinically and radiologically in all patients; 92.3% in group 1 and 46.8% in group 2 were also microbially confirmed. Mixed infections were present in most patients. 3 of 26 patients (11.5%) in group 1 and 9 of 32 (20.1%) in group 2 did not recover while 88.5% in group 1 and 71.9% in group 2 recovered. CIP + VAN seems to be more effective in treating pneumonia in neutropenic patients, with only 1 patient in the group suffering an adverse effect compared with 5 in group 2.
58例确诊为支气管肺炎的粒细胞减少患者被回顾性地分为两组进行这项初步研究：第1组包括接受环丙沙星（CIP；200 - 300mg，静脉注射，每日两次）+万古霉素（VAN；0.5 - 1g，静脉注射，每日两次）治疗的有静脉导管的中性粒细胞减少患者，第2组包括接受头孢他啶（2g，静脉注射，每日三次）+庆大霉素（1mg/kg，静脉注射，每日三次）治疗的无静脉导管患者。所有患者均通过临床和影像学诊断肺炎；第1组92.3%和第2组46.8%的患者也通过微生物学得到确诊。大多数患者存在混合感染。第1组26例患者中有3例（11.5%）未康复，第2组32例中有9例（20.1%）未康复，而第1组88.5%和第2组71.9%的患者康复。CIP + VAN似乎在治疗中性粒细胞减少患者的肺炎方面更有效，第1组仅有1例患者出现不良反应，而第2组有5例。
